PCN3 POPULATION-BASED BUDGET IMPACT MODEL OF APREPITANT (EMEND) IN HIGHLY EMETOGENIC CISPLATINE-BASED CHEMOTHERAPY  by Le Lay, K et al.
A33Abstracts
OBJECTIVE: To examine the responsiveness to change of the
Spanish version of the Juniper Mini Asthma Quality of Life
Questionnaire (Mini-AQLQ). METHODS: 253 patients with
mild to moderate uncontrolled asthma (patients with sympto-
matology and/or need for short-acting ƒ≤2-agonists) were
included in the study (61% women, mean age 36 years). A full
history and physical examination were performed and mon-
telukast was added at the baseline visit. All subjects completed
the Mini-AQLQ questionnaire twice: at recruitment and after
two months. Differences in patient scores before and after the
montelukast addition were analysed using paired t-test. Respon-
siveness was assessed by calculating the standardized effect size
(SES). A within-subject change in score of 0.5 is deﬁned as the
minimal clinically important difference (MCID). RESULTS: The
Mini-AQLQ was responsive to changes over a two-month
period. All Mini-AQLQ global and domain scores signiﬁcantly
improved after montelukast addition (p < 0.01 for all compar-
isons). Mini-AQLQ score changes were signiﬁcantly different for
patients who improved and those that remained stable or dete-
riorated (p < 0.001). The global score effect size was 0.91,
ranging from 0.5 to 1.0 for the domains. The percentage of
patients with mild and moderate asthma who were considered
to have experienced a MCID in global score was 57.5% and
71.4% respectively, with average baseline scores of 5.0 and 4.3
respectively. The domain that experienced the greatest number
of patients experiencing a clinically important improvement was
Symptoms, with 65% and 78% of patients with mild and mod-
erate asthma respectively. CONCLUSIONS: The Spanish version
of the Mini-AQLQ is suitable for use in longitudinal studies
where it is appropriate to assess the impact of asthma on the
quality of life of individual patients with mild to moderate
asthma. A high proportion of patients experienced a clinically
meaningful improvement in their Quality of Life after addition
of montelukast to their asthma therapy.
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OBJECTIVE: To undertake cost-effectiveness evaluation of
pemetrexed/cisplatin (pem/cis) compared to cisplatin (cis) for
patients with advanced malignant pleural mesothelioma (MPM)
in Scotland. METHOD: The efﬁcacy of pem/cis versus cis was
evaluated in the ﬁrst randomised phase III trial in patients with
unresectable MPM (Vogelzang 2003). Emergent data early in the
trial led to patients being fully supplemented with folic acid and
vitamin B12. Survival beneﬁt was assessed in fully vitamin-sup-
plemented patients with advanced disease [FS (stage III/IV)]. A
cost/life-year saved (LYS) analysis of FS (stage III/IV) cohort
using the median survival gain from the clinical trial was under-
taken. This cohort was chosen because it represented the most
realistic use of pemetrexed in Scottish clinical practice: most
MPM patients in Scotland have advanced disease at presentation
(Aziz 2002) and vitamin supplementation is mandatory with
pemetrexed treatment (ALIMTA SPC). Speciﬁc unit costs were
applied to drug acquisition, administration, supportive care med-
ication, hospitalisations for serious adverse events and post-
study chemotherapy, with incidence derived directly from the
clinical trial. A discount rate of 3.5% per annum was applied to
all outcomes. RESULTS: The survival of pem/cis over cisplatin
in this cohort was 13.2 versus 8.4 months (p = 0.003; HR 0.63
[95%CI 0.46–0.86]). The incremental per patient cost for
pem/cis compared to cis was £8196. The incremental cost/LYS
for this cohort is £20,844. The robustness of the model was
tested using one-way sensitivity analyses on key variables affect-
ing both cost and outcomes estimates in the cost-effectiveness
model. Little variation in the incremental cost/LYS was found
with the variables tested for the FS with advanced disease
patients (£17,500–£25,000). CONCLUSIONS: The trial demon-
strated clear survival gain for the cohort of fully supplemented
pem/cis patients with advanced disease. This analysis demon-
strates that the combination may be considered a cost-effective
treatment for patients with advanced MPM.
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OBJECTIVES: Historical evaluations of patients in clinical trials
suggest that patients with advanced nonsmall cell lung cancer
(NSCLC) treated with chemotherapy can expect a two-week
improvement of median survival. We postulated that, with the
publication of randomized trials showing survival improve-
ments, this apparent gain might be attributable to lead time
effects; that is, patients being treated earlier in the natural history
of their disease. METHODS: Patients with Stage IIIb and IV
nonsmall lung cancer were identiﬁed from the SEER-Medicare
database, and population-based cancer registry linked to
Medicare claims. Survival for consecutive cohorts diagnosed
between 1994 and 1999 was analyzed to determine differences
from time of diagnosis to time of treatment and for overall time
from diagnosis to death. RESULTS: During this period 11,995
patients were diagnosed with stages IIIB and IV NSCLC. The
mean age was 75 years, 57% were males and distribution by race
was: 82.4% white, 9.4% African Americans, 3.2% Asian, 1.2%
Hispanic, and 3.7% others. 30% were treated with chemother-
apy. The mean time to chemotherapy initiation in 1994 was 1.63
months while in 1999 was 1.34 (p = 0.0004). This change rep-
resents a difference in treatment initiation of 8.7 days, or almost
62% of the survival beneﬁt observed in the historical clinical trial
evaluation covering 25 years. CONCLUSIONS: Over time there
has been a trend towards earlier initiation of chemotherapy 
following diagnosis in advanced NSCLC. If the date from
chemotherapy initiation is used as a starting point for survival
analyses, as is frequently the case, researchers might erroneously
conclude that survival is improving due to treatment, when in
fact much of the apparent gains are simply due to patients receiv-
ing treatment earlier in the history of their disease.
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OBJECTIVES: To evaluate the economic impact of the intro-
duction in the French market in 2003 of the new agent Aprepi-
tant for the prevention of acute and delayed nausea and vomiting
associated with Highly Emetogenic cisplatine-based cancer
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Chemotherapy. METHODS: An analysis of the IMS Health
ONCO Combined, LMPH, EHPP, GERS databases allowed
identifying the anti-emetic schemes used in this indication in
2002, to draw up the market trend in ambulatory care and in
hospital, and to determine the cost of corresponding consump-
tion. A budget impact model was built over 4 years with several
scenarii. The results are reported for 10,000 HEC cycles with a
reduction in the use of the cisplatin of 5% per year, a 10%, 15%,
20%, 25% penetration rate of aprepitant, and a substitution rate
in the delayed phase increasing from 30% to 90% over the
period. RESULTS: The market share of 5-HT3 receptor antago-
nists was equal to 76% of the HEC market in 2002. In ambu-
latory care, the average cost of setrons in acute phase d1 and
both in acute and delayed phases amounts respectively €26.90
and €111.25 per chemotherapy cycle. In hospital the corre-
sponding ﬁgures are €33.02 and €147.50. The antiemetic treat-
ment cost without aprepitant rises to €774,000 the ﬁrst year 
and to €664,000 the fourth year. The net budget impact due to
the introduction of aprepitant is €46,000 the ﬁrst year and
€41,000 the fourth year, i.e. less than 6% each year. In ambula-
tory care, this differential is €23,000 the ﬁrst year and becomes
nearly null cost over the four years. CONCLUSION: The 
overcost generated by the use of aprepitant is small for the
French sickness funds compared to the overall antiemetic 
treatment cost.
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OBJECTIVES: The aim of this study was to estimate costs of
care associated with metastatic colorectal cancer (MCCR) in
current clinical practice and the potential impact on the Spanish
health care budget of cetuximab prescription to patients with
MCCR. METHODS: In order to describe treatment patterns and
to analyse costs of MCCR, a cost of care treatment model was
constructed. The economic impact of cetuximab was estimated
by means of a treatment model for third-line use of the cetux-
imab combination after second-line irinotecan failure. Treatment
patterns were obtained from questionnaires ﬁlled out by 14
Spanish hospitals and from an advisory board of 5 clinical
experts. Treatment algorithms were constructed by using Tree
Age Data Pro software. In order to estimate the unit costs, Diag-
nostic Related Groups were used for inpatient services, while
outpatient services were calculated on daily based rates. Unit
costs were obtained from national databases (€2004). The treat-
ment costs were calculated from the perspective of the Spanish
National Health System. The incidence of MCCR was obtained
from literature review. RESULTS: For a population of 10,350
patients with MCCR in Spain, the total cost (pharmacological
and medical costs) was estimated in €151 million. In that sce-
nario, the cost of care of patients at third-line therapy that had
failed to irinotecan therapy amounted €1.5 million. With the
introduction of cetuximab after second-line irinotecan failure, a
maximum of 193 patients were estimated to be eligible for the
new drug. In this scenario, the total cost of the third-line therapy
would come to €4.7 million. CONCLUSIONS: Cetuximab in
combination with irinotecan is the only third-line therapy indi-
cated in MCCR after irinotecan failure. If the eligible patients in
third-line therapy received cetuximab and irinotecan instead of
current clinical practice, the economic impact of substitution
would amount €3.2 million.
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OBJECTIVES: To evaluate direct treatment cost associated with
pegylated liposomal doxorubicin hydrochloride (PLD) and
topotecan used as second line therapies for ovarian cancer in
Poland. METHODS: The literature review showed topotecan
and PLD have similar efﬁcacy in platinum-refractory or platinum
resistant advanced ovarian cancer but different adverse events
proﬁle. The cost-minimization analysis was performed from the
payer’s perspective. Only direct medical costs (i.e. drug acquisi-
tion costs, drug administration costs and managing adverse
events costs) were included. Based on epidemiological data bud-
getary impact of PLD treatment in Poland was estimated.
RESULTS: The acquisition and drug administration costs were
estimated at €12,448 and €6935 for PLD and topotecan, while
cost of managing adverse events at €134 and €1234 for PLD and
topotekan, respectively. The total cost per patient summed up to
€12,882 for PLD and €8169 for topotecan. 38% reduction in
acquisition cost of PLD would balance topotecan associated
costs. Epidemiological data indicated 985 platinum-resistant or
platinum-refractory ovarian cancer patients in Poland were eli-
gible annually for treatment with PLD, thus additional cost could
be estimated at €4.64 million. CONCLUSIONS: PLD represents
attractive treatment strategy in second line therapy of platinum-
resistant or platinum-refractory ovarian cancer, although acqui-
sition cost reduction is necessary were compared to topotecan in
Polish settings.
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The clinical study phase III 071 has showed the new antiemetic
Aprepitant in association with a standard therapy (corticosteroid
plus a 5-HT3 receptor antagonist) increases signiﬁcantly the
complete response (no vomiting and no rescue treatment) by
more than 10 points compared to the standard therapy used in
MEC. OBJECTIVES: To evaluate the budget impact implied by
the introduction of this new antiemetic on the French sickness
funds. METHODS: The MEC were deﬁned according to the rec-
ommendations of the Multinational Association of Supportive
Care in Cancer (2004). A sample of patients was extracted from
the ONCO IMS 2004 database. The inclusion criteria used were:
to receive a MEC in association with an antiemetic one con-
taining a corticosteroid and a 5-HT3 receptor antagonist and to
have this treatment during the acute and delayed periods. Prices
of the antiemetic treatments were taken from the GERS 2004
database. A budget impact model was implemented over a period
of four years, based on a stable population and on different pen-
etration and substitution rates of Aprepitant. RESULTS: The
results are reported for 10,000 MEC cycles associated to the
standard therapy. The penetration and substitution rates of
Aprepitant increase over the period from 10% to 25% and from
70% to 95%, respectively. In 2004, the treatment cost is
€466,000. The introduction of Aprepitant increases the cost of
the acute phase but decreases it in the delayed one. In the ambu-
